Pasithea Therapeutics Corp.
Nasdaq · Healthcare · Pharmaceutical Preparations · Miami Beach, FL
KTTA chart
What traders are saying about $KTTA
Latest postsPasithea Therapeutics Corp. news
- Pasithea Therapeutics Corp. expected to post a loss of 21 cents a share - Earnings Preview
TradingView ·
- Pasithea Therapeutics | SCHEDULE 13G/A: Others
Moomoo ·
- Pasithea Therapeutics Stock Price Forecast. Should You Buy KTTA?
StockInvest.us ·
- Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Yahoo Finance ·
- Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Yahoo Finance ·
- Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Yahoo Finance ·
- Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Yahoo Finance ·
- Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Yahoo Finance ·
- New Strong Buy Stocks for July 20th
Yahoo Finance ·
- Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Yahoo Finance ·
- Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Yahoo Finance ·
- Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Yahoo Finance ·
Pasithea Therapeutics Corp. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $486,559 |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M |
| Diluted EPS | $-2.91 | $-12.69 | $-0.42 | $-1.76 |
| Total assets (year end) | $60.2M | $16.1M | $26.1M | $45.2M |
| Cash and equivalents (year end) | $55.2M | $6.9M | $16.3M | $33.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Pasithea Therapeutics Corp.
- Ticker
- KTTA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Miami Beach, FL
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1841330
Frequently asked questions
What exchange is Pasithea Therapeutics Corp. listed on?
Pasithea Therapeutics Corp. trades on the Nasdaq under the ticker symbol KTTA.
What industry is Pasithea Therapeutics Corp. in?
Pasithea Therapeutics Corp. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Pasithea Therapeutics Corp. headquartered?
Pasithea Therapeutics Corp.'s business address on file with the SEC is in Miami Beach, FL.
When does Pasithea Therapeutics Corp.'s fiscal year end?
Pasithea Therapeutics Corp.'s fiscal year ends on December 31.
How much revenue did Pasithea Therapeutics Corp. report?
Pasithea Therapeutics Corp. reported $486,559 in revenue for calendar year 2022, according to its SEC filings.